BELLUS Health Inc (BLU.CA) Page | The Online Investor

BELLUS Health Inc (BLU.CA)

BELLUS Health is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Co.'s primary product candidate, BLU-5937, is a selective and potentially antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. Co. is developing BLU-5937 for the treatment of adults with RCC.

BLU.CA — Key Stats (updated Thu., Jun. 22, 10:36 AM)

Company Name:
BELLUS Health Inc
Website:
www.bellushealth.com
Sector:
Biotechnology

BLU.CA — News

BLU.CA — Price Chart

BLU.CA — Current Quote

Quotes delayed 20 minutes

Free BLU.CA Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

BLU.CA — Performance

BELLUS Health Inc (BLU.CA) Page | The Online Investor Page | www.TheOnlineInvestor.com

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.